YOLFTbeta
Ascendis Pharma AS

Ascendis Pharma AS

ASND · NASDAQ · Healthcare / Biotechnology

275.39USD+8.32 (+3.12%)

Price History

Full chart

Market Stats

Previous Close267.07
Open267.40
Day Range265.62 – 278.56
52-Week Range186.05 – 282.15
Volume822.48K
Market Cap15.18B
P/E (TTM)17.39
Forward P/E19.84
EPS13.27
Dividend Yield0.00%
Beta0.48
50-Day Avg252.01
200-Day Avg234.98

About

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jan Moller Mikkelsen
  • Employees1.19K
  • HeadquartersTuborg Boulevard 12, Hellerup, Denmark, 2900, USA
  • Websitehttps://ascendispharma.com

Leadership

  • Mr. Jan Moller MikkelsenPresident, CEO, Member of Executive Board & Executive Director · b. 1960
  • Mr. Scott T. SmithCFO, Executive VP & Member of Executive Board · b. 1974
  • Ms. Pedersen Anni Lotte Kirstine SonderbjergExecutive VP, Chief Administrative Officer & Member of the Executive Board · b. 1961
  • Mr. Michael Wolff Jensen L.L.M.Executive VP, Chief Legal Officer & Member of the Executive Board · b. 1971
  • Mr. Mads BodenhoffSenior VP, Head of Finance & Principal Accounting Officer · b. 1970
  • Mr. Chad FugureVice President of Investor Relations
  • Mr. Flemming Steen JensenExecutive Vice President of Product Supply & Quality · b. 1961
  • Dr. Kennett Sprogoe Ph.D.Executive VP and Head of Research & Product Development · b. 1979
  • Mr. Joseph KellyHead of U.S. Commercial of Endocrinology · b. 1969
  • Ms. Sherrie Lynn GlassChief Business Officer · b. 1972

Financials

Income Statement

Currency: EUR2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue15.58M20.41M13.98M8.12M4.61M1.53M10.58M13.38M6.95M7.78M51.17M266.72M363.64M691.71M
Growth (%)-+30.96%-31.48%-41.94%-43.26%-66.78%+591.57%+26.41%-48.01%+11.87%+557.93%+421.20%+36.34%+90.22%
Cost of Revenue-037.28M35051.69T6.64T1000000.00T0003.52M12.14M44.40M44.26M103.18M
Gross Profit15.58M20.41M13.98M8.12M4.61M1.53M10.58M13.38M6.95M4.25M39.04M222.32M319.38M588.53M
Gross Margin100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%54.71%76.28%83.36%87.83%85.08%
Operating Expense14.07M15.13M25.97M49.94M77.53M113.07M165.34M240.09M337.57M456.05M600.85M677.86M598.15M719.42M
Operating Income1.51M5.28M-11.99M-41.83M-72.92M-111.54M-154.76M-226.72M-330.62M-451.79M-561.81M-455.54M-278.76M-130.89M
Operating Margin9.71%25.87%-85.74%-515.21%-1583.15%-7290.26%-1462.59%-1695.10%-4755.07%-5808.59%-1097.85%-170.79%-76.66%-18.92%
EBITDA1.73M5.68M-11.48M-33.01M-72.12M-109.88M-150.18M-210.36M-407.81M-364.64M-529.18M-411.17M-290.02M-109.80M
EBITDA Margin11.10%27.85%-82.14%-406.63%-1565.78%-7181.96%-1419.32%-1572.79%-5865.21%-4688.12%-1034.07%-154.16%-79.76%-15.87%
Net Income1.25M4.08M-9.66M-32.92M-68.50M-123.90M-130.10M-218.02M-418.95M-383.58M-583.19M-481.45M-378.08M-219.03M
Net Income Margin8.02%19.99%-69.07%-405.54%-1487.30%-8097.84%-1229.53%-1630.03%-6025.53%-4931.56%-1139.63%-180.51%-103.97%-31.67%
R&D11.38M12.71M19.70M40.53M66.02M99.59M140.28M191.62M260.90M295.87M379.62M413.45M307.00M283.50M
R&D as % of Total Revenue73.03%62.29%140.87%499.24%1433.39%6509.08%1325.78%1432.68%3752.39%3803.90%741.83%155.02%84.43%40.99%
Interest Expense20.00K8.00K16.00K6.00K5.00K97.00K127.00K1.22M1.92M3.91M30.68M44.06M65.50M77.46M
Interest Expense % of Total Revenue0.13%0.04%0.11%0.07%0.11%6.34%1.20%9.13%27.59%50.28%59.96%16.52%18.01%11.20%

Balance Sheet

Currency: EUR2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets22.82M25.41M26.70M58.67M131.77M190.07M210.98M318.97M676.73M979.79M1.08B1.09B825.59M1.18B1.30B
Total Liabilities22.59M23.85M20.40M12.86M11.45M13.46M23.77M38.92M79.62M141.08M201.29M826.39M971.28M1.29B1.46B
Total Equity233.00K1.56M6.30M45.81M120.33M176.61M187.21M280.05M597.11M838.71M883.63M263.35M-145.70M-105.71M-162.75M
Cash15.68M14.54M19.43M50.17M119.65M180.33M195.35M277.86M598.11M584.52M446.27M444.77M392.16M559.54M615.78M
Total Debt400.00K212.00K--000036.62M91.97M209.92M617.57M743.06M856.62M871.41M
Net Debt-15.28M-14.32M-19.43M-50.17M-119.65M-180.33M-195.35M-277.86M-561.49M-492.54M-236.34M172.80M350.89M297.07M255.64M

Cash Flow

Currency: EUR2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-652.00K6.31M-18.40M-43.47M-60.18M-95.10M-138.80M-175.94M-271.55M-417.65M-495.70M-467.36M-306.20M51.77M
Investing Cash Flow-291.00K-1.20M-405.00K-1.04M-672.00K-941.00K-2.65M-5.16M-291.20M-110.58M61.73M286.47M6.88M-8.15M
Financing Cash Flow-205.00K-220.00K47.91M105.74M117.46M124.72M203.27M493.59M602.65M351.39M396.77M134.29M443.93M34.89M
Capital Expenditure291.00K1.20M405.00K1.04M672.00K941.00K2.65M5.16M21.55M24.23M14.49M2.44M1.43M8.15M
Free Cash Flow-943.00K5.12M-18.81M-44.51M-60.85M-96.04M-141.45M-181.09M-293.10M-441.88M-510.19M-469.80M-307.62M43.62M
Dividends Paid--000000-33.14M5.06M---
FCF to OCF144.63%81.06%102.20%102.39%101.12%100.99%101.91%102.93%107.94%105.80%102.92%100.52%100.47%84.26%
Dividend Paid to FCF--0.00%0.00%0.00%0.00%0.00%0.00%--7.50%-0.99%---

Earnings

Report DateMar 25, 2015May 18, 2015Aug 24, 2015Nov 12, 2015Apr 14, 2016Aug 31, 2016Nov 30, 2016Mar 22, 2017May 23, 2017Aug 18, 2017Nov 16, 2017Mar 28, 2018May 30, 2018Aug 29, 2018Nov 28, 2018Dec 31, 2018May 30, 2019Aug 28, 2019Nov 18, 2019Dec 31, 2019May 19, 2020Aug 27, 2020Nov 11, 2020Mar 10, 2021May 27, 2021Aug 25, 2021Nov 10, 2021Mar 2, 2022May 11, 2022Aug 10, 2022Nov 2, 2022Feb 16, 2023Apr 27, 2023Sep 5, 2023Nov 7, 2023Feb 7, 2024May 2, 2024Sep 3, 2024Nov 14, 2024Feb 12, 2025May 1, 2025Aug 7, 2025Nov 12, 2025Feb 11, 2026Apr 30, 2026Aug 13, 2026Nov 11, 2026
EPS Estimate--0.24-0.38-0.53-0.28-0.58-0.60-0.62-0.70-0.74-0.73-0.80-0.74-0.86-1.02-1.14-1.02-1.20-1.16-1.62-1.30-1.44-1.59-1.55-1.90-2.23-2.29-2.34-1.99-2.25-2.53-2.56-2.62-2.59-2.25-1.76-1.42-1.46-1.46-1.17-1.51-1.42-0.12-0.240.430.781.13
EPS Actual-0.650.06-0.63-0.30-0.52-0.53-0.72-0.67-0.78-0.94-1.04-0.92-1.07-0.55-0.81-0.86-1.24-1.25-0.53-1.89-1.32-1.97-2.31-2.64-1.17-2.50-1.47-1.87-2.21-1.46-3.03-3.70-1.98-2.16-2.88-1.54-2.30-2.11-1.72-0.64-1.58-0.93-1.00-0.550.273.29-
Surprise-125.00%-65.79%43.40%-85.71%8.62%-20.00%-8.06%-11.43%-27.03%-42.47%-15.00%-44.59%36.05%20.59%24.56%-21.57%-4.17%54.31%-16.67%-1.54%-36.81%-45.28%-70.32%38.42%-12.11%35.81%20.09%-11.06%35.11%-19.76%-44.53%24.43%16.60%-28.00%12.50%-61.97%-44.52%-17.81%45.30%-4.64%34.51%-733.33%-129.17%-37.21%321.79%-
TimingAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market-

Key Statistics & Ratios

Market Cap15.18B
Enterprise Value14.26B
Trailing P/E17.39
Forward P/E19.84
Price / Sales14.49
Price / Book8.91
EPS13.27
Book Value24.89
Revenue (TTM)1.05B
Gross Profit (TTM)955.89M
EBITDA263.45M
Profit Margin70.85%
Operating Margin64.98%
Return on Equity118.78%
Return on Assets9.58%
Shares Outstanding65.78M
Shares Float65.64M
Beta0.48
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 16 analystsTarget 310.26
  • Strong Buy
    12
  • Buy
    4

Ownership Breakdown

Institutions
104.02%
Insiders
0.78%
Retail / Other
0.00%

Top Institutional Holders

  • RA Capital Management, LLC
    10.28M16.75%
  • venBio Select Advisor LLC
    5.06M8.25%
  • FMR Inc
    3.88M6.32%
  • Franklin Templeton Inc
    2.05M3.34%
  • Massachusetts Financial Services Company
    1.86M3.03%
  • BlackRock Inc
    661.05K1.08%
  • Polar Capital Holdings PLC
    651.71K1.06%
  • Morgan Stanley - Brokerage Accounts
    606.35K0.99%
  • The Goldman Sachs Group Inc
    566.19K0.92%
  • Delaware Management Holdings Inc
    556.43K0.91%
  • JPMorgan Chase & Co
    539.43K0.88%
  • Ameriprise Financial Inc
    476.47K0.78%
  • Fidelity International Ltd
    447.42K0.73%
  • Vestal Point Capital LP
    375.00K0.61%
  • Amvescap Plc.
    362.11K0.59%
  • SEI Investments Co
    351.15K0.57%
  • BNP Paribas Arbitrage, SA
    309.17K0.50%
  • Fred Alger Management, LLC
    304.90K0.50%
  • AllianceBernstein L.P.
    278.20K0.45%
  • Candriam Luxembourg S.C.A.
    230.28K0.38%